poisar

Stocks · News reference

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Avi Kapoor

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BNTCCRWDFTHGOSSHRBJBSKGS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Benitec Biopharma Inc. (BNTC)

    Filed: 2026-09-24 AccNo: 0001193125-26-401110 Size: 163 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits

    BNTC
  3. Na

    Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

    Benitec Biopharma announced completion of 12-month follow-up for all six Cohort 1 patients in its BB-301 Phase 1b/2a trial for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia, with clinically meaningful improvements observed. Cohort 2 is fully enrolled with three patients safely treated. The company held a Type C meeting with the FDA regarding pivotal study design and plans to initiate the pivotal trial in mid-2027. Benitec reported $180 million in cash as of June 30, 2026, with operating expenses of $51.2 million for fiscal year 2026.

    BNTC
  4. Benzinga Newsdesk

    Benitec Biopharma Q4 EPS $(0.26), Inline

    Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.

    BNTC